全文获取类型
收费全文 | 24064篇 |
免费 | 1456篇 |
国内免费 | 113篇 |
专业分类
耳鼻咽喉 | 265篇 |
儿科学 | 532篇 |
妇产科学 | 551篇 |
基础医学 | 3209篇 |
口腔科学 | 709篇 |
临床医学 | 1928篇 |
内科学 | 6338篇 |
皮肤病学 | 589篇 |
神经病学 | 2115篇 |
特种医学 | 596篇 |
外科学 | 3543篇 |
综合类 | 136篇 |
现状与发展 | 1篇 |
一般理论 | 4篇 |
预防医学 | 1811篇 |
眼科学 | 435篇 |
药学 | 1204篇 |
中国医学 | 58篇 |
肿瘤学 | 1609篇 |
出版年
2023年 | 176篇 |
2022年 | 128篇 |
2021年 | 875篇 |
2020年 | 398篇 |
2019年 | 791篇 |
2018年 | 891篇 |
2017年 | 538篇 |
2016年 | 561篇 |
2015年 | 657篇 |
2014年 | 909篇 |
2013年 | 1194篇 |
2012年 | 1927篇 |
2011年 | 1843篇 |
2010年 | 1070篇 |
2009年 | 997篇 |
2008年 | 1552篇 |
2007年 | 1598篇 |
2006年 | 1517篇 |
2005年 | 1488篇 |
2004年 | 1223篇 |
2003年 | 1189篇 |
2002年 | 1106篇 |
2001年 | 238篇 |
2000年 | 213篇 |
1999年 | 229篇 |
1998年 | 187篇 |
1997年 | 179篇 |
1996年 | 108篇 |
1995年 | 152篇 |
1994年 | 119篇 |
1993年 | 109篇 |
1992年 | 145篇 |
1991年 | 128篇 |
1990年 | 91篇 |
1989年 | 92篇 |
1988年 | 81篇 |
1987年 | 70篇 |
1986年 | 84篇 |
1985年 | 78篇 |
1984年 | 65篇 |
1983年 | 42篇 |
1982年 | 43篇 |
1981年 | 43篇 |
1980年 | 36篇 |
1979年 | 45篇 |
1978年 | 44篇 |
1976年 | 40篇 |
1975年 | 28篇 |
1974年 | 28篇 |
1970年 | 25篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Adjuvant irradiation is the standard treatment after breast conservative surgery. Normofractionated regimen with an overall treatment time of 5 to 6 weeks is often considered as a limiting factor for irradiation compliance. In order to answer this issue, moderate and more recently extreme hypofractionated protocols appeared. We report here oncological outcomes and toxicity of hypofractionated breast irradiation. After defining the frame of moderate and extreme hypofractionated breast irradiations based on overall treatment time, patient selection criteria were listed. According to their levels of proof, the results of moderate and extreme hypofractionated breast irradiation were analysed. Overall treatment time for moderate hypofractionated breast irradiation ranged from 3 to 4 weeks, while for extreme hypofractionated breast irradiation, it was less than 1 week. For moderate hypofractionated breast irradiation, whole breast irradiation was currently performed with or without lymph node irradiation. Moderate hypofractionated breast irradiation has proven to be as safe and as efficient as normofractionated breast irradiation with level IA evidence. For extreme hypofractionated breast irradiation, phase III randomized trials confirmed that accelerated partial breast irradiation was non-inferior in terms of local control compared to normofractionated whole breast irradiation (with external beam radiation therapy and multicatheter brachytherapy), with similar acute and late toxicity. While the use of intraoperative breast irradiation remains under debate, new very accelerated partial breast irradiation (overall treatment time not exceeding 2 days) protocols emerged with encouraging results. Accelerated partial breast irradiation is warranted for extreme hypofractionated breast irradiation and is indicated for low-risk breast cancers. Moderate and extreme hypofractionated breast irradiation regimens are validated and can be routinely proposed according to patient selection criteria. 相似文献
3.
4.
5.
6.
Jose M. Morales Jose Angel Martinez-Flores Manuel Serrano Maria José Castro Francisco Javier Alfaro Florencio García Miguel Angel Martínez Amado Andrés Esther González Manuel Praga Estela Paz-Artal Antonio Serrano 《Journal of the American Society of Nephrology : JASN》2015,26(3):735-745
In the current immunosuppressive therapy era, vessel thrombosis is the most common cause of early graft loss after renal transplantation. The prevalence of IgA anti–β2-glycoprotein I antibodies (IgA-aB2GPI-ab) in patients on dialysis is elevated (>30%), and these antibodies correlate with mortality and cardiovascular morbidity. To evaluate the effect of IgA-aB2GPI-ab in patients with transplants, we followed all patients transplanted from 2000 to 2002 in the Hospital 12 de Octubre prospectively for 10 years. Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively. Of 269 patients, 89 patients were positive for IgA-aB2GPI-ab (33%; group 1), and the remaining patients were negative (67%; group 2). Graft loss at 6 months post-transplant was significantly higher in group 1 (10 of 89 versus 3 of 180 patients in group 2; P=0.002). The most frequent cause of graft loss was thrombosis of the vessels, which was observed only in group 1 (8 of 10 versus 0 of 3 patients in group 2; P=0.04). Multivariate analysis showed that the presence of IgA-aB2GPI-ab was an independent risk factor for early graft loss (P=0.04) and delayed graft function (P=0.04). There were no significant differences regarding patient survival between the two groups. Graft survival was similar in both groups after 6 months. In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early graft loss caused by thrombosis and a high risk of delayed graft function. Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effect on early clinical outcomes after renal transplantation. 相似文献
7.
8.
Ruiz-Úcar Elena Acín-Gándara Débora Medina-García Manuel Ronda Diego Cruzado Pereira-Pérez Fernando 《Obesity surgery》2022,32(2):569-570
Obesity Surgery - Laparoscopic sleeve gastrectomy (LSG) is increasingly playing a key role in obesity management. Such operations, however, carry complications sometimes including leaks. The... 相似文献
9.